| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Total revenue | ||||||||||
2,072,600 | 1,895,600 | 1,765,900 | 1,611,300 | 1,623,800 | 1,808,900 | 1,839,400 | 1,791,400 | 1,651,700 | 1,304,900 | 1,114,500 |
Total cost of revenue | ||||||||||
1,077,300 | 995,600 | 949,900 | 866,000 | 915,200 | 1,045,600 | 1,034,200 | 962,000 | 899,200 | 700,900 | 597,000 |
Gross profit | ||||||||||
995,300 | 900,000 | 816,000 | 745,300 | 708,600 | 763,300 | 805,200 | 829,400 | 752,500 | 604,000 | 517,500 |
Operating expenses: | ||||||||||
Selling, general and administrative | ||||||||||
500,200 | 444,700 | 415,200 | 389,800 | 392,200 | 451,000 | 437,900 | 440,400 | 406,600 | 301,100 | 254,000 |
Research and development | ||||||||||
187,700 | 173,400 | 161,600 | 147,900 | 145,700 | 174,200 | 190,500 | 195,300 | 177,200 | 141,400 | 126,400 |
Other charges, net | ||||||||||
6,500 | 19,500 | 19,700 | 25,800 | 25,000 | 32,700 | 28,600 | 13,900 | 9,700 | 5,800 | 400 |
Impairment of assets | ||||||||||
- | - | - | - | - | - | - | 23,800 | - | - | - |
Write-off of deferred offering costs | ||||||||||
- | - | - | - | - | - | - | - | 3,400 | - | - |
Total operating expenses | ||||||||||
694,400 | 637,600 | 596,500 | 563,500 | 562,900 | 657,900 | 657,000 | 673,400 | 596,900 | 448,300 | 380,800 |
Operating income | ||||||||||
300,900 | 262,400 | 219,500 | 181,800 | 145,700 | 105,400 | 148,200 | 156,000 | 155,600 | 155,700 | 136,700 |
Interest and other income (expense), net | ||||||||||
-20,500 | -17,700 | -21,700 | -4,200 | -17,700 | -4,100 | -23,600 | -17,700 | -10,100 | -5,600 | -7,600 |
Income before income taxes and noncontrolling interest in consolidated subsidiaries | ||||||||||
280,400 | 244,700 | 197,800 | 177,600 | 128,000 | 101,300 | 124,600 | 138,300 | 145,500 | 150,100 | 129,100 |
Income tax provision | ||||||||||
82,400 | 63,700 | 117,500 | 23,100 | 23,100 | 41,700 | 42,800 | 60,100 | 51,500 | 53,300 | 48,100 |
Consolidated net income | ||||||||||
198,000 | 181,000 | 80,300 | 154,500 | 104,900 | 59,600 | 81,800 | 78,200 | 94,000 | 96,800 | 81,000 |
Net income attributable to noncontrolling interests in consolidated subsidiaries | ||||||||||
800 | 1,300 | 1,700 | 900 | 3,300 | 2,900 | 1,700 | 700 | 1,700 | 1,400 | -200 |
Net income attributable to Bruker Corporation | ||||||||||
197,200 | 179,700 | 78,600 | 153,600 | 101,600 | 56,700 | 80,100 | 77,500 | 92,300 | 95,400 | 81,200 |
Net income per common share attributable to Bruker Corporation shareholders: | ||||||||||
Basic (in dollars per share) | ||||||||||
1.27 | 1.15 | 0.50 | 0.95 | 0.60 | 0.34 | 0.48 | 0.47 | 0.56 | 0.58 | 0.50 |
Diluted (in dollars per share) | ||||||||||
1.26 | 1.14 | 0.49 | 0.95 | 0.60 | 0.33 | 0.48 | 0.46 | 0.55 | 0.58 | 0.49 |
Weighted average common shares outstanding: | ||||||||||
Basic (in shares) | ||||||||||
155,200 | 156,200 | 158,100 | 161,400 | 168,200 | 167,800 | 166,500 | 166,000 | 165,400 | 164,400 | 163,500 |
Diluted (in shares) | ||||||||||
156,600 | 157,200 | 159,100 | 162,200 | 169,100 | 169,500 | 168,500 | 167,400 | 166,900 | 165,700 | 164,900 |
Consolidated net income | ||||||||||
198,000 | 181,000 | 80,300 | 154,500 | 104,900 | 59,600 | 81,800 | 78,200 | 94,000 | 96,800 | 81,000 |
Foreign currency translation (net of tax of $5.1 million, $4.4 million and $4.0 million respectively) adjustments | ||||||||||
-20,000 | -25,500 | 97,100 | -27,600 | -63,800 | -131,700 | 27,300 | 8,800 | -14,700 | 8,100 | - |
Changes in hedging instruments | ||||||||||
- | - | - | - | - | - | - | 1,100 | 1,900 | 500 | - |
Pension liability adjustments (net of tax of $6.3 million, $3.8 million and $2.9 million, respectively) | ||||||||||
23,000 | -15,300 | -6,500 | 4,400 | 9,600 | 22,600 | -17,300 | 15,000 | -2,900 | -9,900 | - |
Comprehensive income (loss) | ||||||||||
155,000 | 170,800 | 183,900 | 122,500 | 31,500 | -94,700 | 126,400 | 73,100 | 84,100 | 95,500 | - |
Less: Comprehensive income (loss) attributable to noncontrolling interests | ||||||||||
1,800 | 1,300 | 2,400 | 600 | 2,300 | 2,800 | 1,600 | 300 | 1,700 | 1,200 | - |
Comprehensive income (loss) attributable to Bruker Corporation | ||||||||||
154,700 | 169,700 | 181,500 | 121,900 | 29,200 | -97,500 | 124,800 | 72,800 | 82,400 | 94,300 | - |
Dividend declared per common share (in dollars per share) | ||||||||||
- | - | - | 0.16 | - | - | - | - | - | - | - |
Product | ||||||||||
Total revenue | ||||||||||
1,744,700 | 1,576,600 | 1,479,500 | 1,345,400 | 1,381,100 | 1,571,900 | 1,611,400 | 1,556,500 | 1,445,600 | 1,145,400 | 985,300 |
Total cost of revenue | ||||||||||
878,500 | 801,100 | 787,700 | 711,400 | 774,200 | 896,000 | 891,700 | 837,200 | 792,500 | 621,500 | 526,300 |
Service | ||||||||||
Total revenue | ||||||||||
322,400 | 311,700 | 278,200 | 254,700 | 235,500 | 231,800 | 219,300 | 210,000 | 194,800 | 151,100 | 122,400 |
Total cost of revenue | ||||||||||
198,300 | 193,400 | 160,800 | 150,000 | 139,700 | 149,600 | 142,500 | 124,800 | 106,700 | 79,400 | 70,700 |
Other | ||||||||||
Total revenue | ||||||||||
5,500 | 7,300 | 8,200 | 11,200 | 7,200 | 5,200 | 8,700 | 24,900 | 11,300 | 8,400 | 6,800 |
Total cost of revenue | ||||||||||
500 | 1,100 | 1,400 | 4,600 | 1,300 | - | - | - | - | - | - |